The miRNomics of antiretroviral therapy-induced obesity

Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 5, 2025

Language: Английский

Efficacy and safety of doravirine/lamivudine/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China

Frontiers in Medicine, Journal Year: 2025, Volume and Issue: 12

Published: May 29, 2025

Background The single-tablet regimen Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) has been included in international guidelines and recommendations was approved by China’s National Medical Products Administration (NMPA) early 2021 for adult human immunodeficiency virus (HIV)-1 infections. This study presents real-world results of a retrospective analysis patients who initiated DOR/3TC/TDF at Chinese HIV center. Methods carried out on received (initial or switch) the outpatient clinic Infection Center Beijing Youan Hospital China. Patients’ baseline characteristics, reasons switching to DOR/3TC/TDF, along with preliminary clinical, laboratory – based efficacy, safety, tolerability data, were collected. All evaluations strict accordance protocols our statistical mainly descriptive, aiming assess changes parameters from data collection deadline, which December 31, 2024. Result From May 16 October 29, 2024, 205 prescribed either as an initiation switch. cohort consisted males (96.1%), median age 36.0 (31.0, 41.0) years. By entire group had used 149.0 (90.0, 202.0) days. Among them, 40 treatment-naïve, HIV-1 ribonucleic acid (HIV-1 RNA) 4.1 (3.7, 4.6) log 10 copies/mL. At weeks 12 24, 64.5% [95% confidence interval (CI): 45.4, 80.8%] 91.3% (95% CI: 72.0, 98.9%) participants achieved RNA < 50 Subgroup showed that high viral load (VL) (≥10 5 copies/mL) low CD4 counts (< 200 cells/μL) did not affect virological efficacy. immune reconstitution also satisfactory, increased 350 (264, 465) cells/μL 541.0 (415.8, 789.5) end follow-up ( p > 0.05). 165 (80.5%) treatment experience, most common cause simplification (40%). After switch, equally proportion [97.6% 93.7, 99.3%) vs. 96.4% 92.2, 98.7%)] undetectable <50 copies/mL Compared baseline, there no significant liver enzymes renal function 0.05), while body weight, random blood glucose lipid levels decreased significantly central nervous system (CNS) symptom, both Pittsburgh Sleep Quality Index (PSQI) Anxiety Depression Scale (HADS) scores, well scores greater than 7 points, post-switch Conclusion We provided observational report effectiveness safety short-term use routine clinical practice.

Language: Английский

No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens

Journal of Antimicrobial Chemotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 30, 2024

Doravirine is licensed in patients living with HIV (PWH) harbouring no prior resistance to any NNRTIs. We aimed evaluate real life the efficacy of doravirine NNRTI virological failure and resistance-associated mutations (RAMs). This observational study included PWH switched a doravirine-containing regimen between 30 September 2019 1 May 2022, an HIV-1 RNA ≤50 copies/mL past NNRTI-RAMs. The main outcome was proportion participants at Week 48 96. Secondary outcomes evaluated rate viral suppression transient blip, RAMs case side effects. A total 102 were analysed, mostly men (63%), median age 59 years (IQR 51-63). time since diagnosis 26 16-31), on ART for 22 14-26) virally suppressed 7 1-11).Of 25/102 (25%) had documented historical doravirine, 9/25 (36%) showing possible 16/25 (64%) major resistance. profile primarily (21/23) consisted K103N, Y181C and/or G190A/E reverse transcriptase substitutions. Median last detection NNRTI-RAMs 12 (5-17). Over 2 follow-up, occurred, neither (0/87; 0%) nor 96 (0/86; 0%). first real-world provide new insight about use regimens as treatment long-term whose viruses harboured specific their history.

Language: Английский